Update on Erdafitinib, a Treatment for Metastatic Urothelial Cancer with Dr. Siefker-Radtke

3 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Arlene O. Siefker-Radtke, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, explores the evolving role of erdafitinib in treating FGFR3-altered urothelial carcinoma. In this 12-minute presentation, Dr. Siefker-Radtke highlights erdafitinib, an FGFR3 inhibitor, as a second-line therapy following chemotherapy and immunotherapy.

Dr. Siefker-Radtke shares results from the THOR trial confirming its efficacy. While response rates were higher with erdafitinib, pembrolizumab exhibited greater long-term benefit, likely due to the durability of immunotherapy responses. Combination strategies with checkpoint inhibitors such as cetrelimab also showed promise. The RAGNAR trial further highlighted the drug’s tumor-agnostic potential.

The optimal sequencing of erdafitinib within treatment paradigms remains an open question, but emerging data suggest that its use following checkpoint inhibition maximizes therapeutic benefit while maintaining durable responses.
Category
Oncology
Be the first to comment

Up Next